Eli Lilly's Global Obesity Drug Ambitions May Outpace U.S. Sales

Eli Lilly's second-quarter results have shifted the conversation around its stock, as the company's performance exceeded Wall Street's expectations and prompted analysts to look beyond the U.S. market for future growth. For much of the year, investor focus was on the slow initial uptake of Lilly's new obesity pill, Foundayo, in the United States. While that concern hasn't vanished, Bank of America is now highlighting a different story: the potential for international obesity drug sales to eventually surpass those in the U.S.

International Growth Takes Center Stage

Bank of America recently raised its price target for Eli Lilly to $1,344 from $1,334, applying a premium valuation multiple based on the company's faster growth compared to other large pharmaceutical firms. The move followed a quarter in which Lilly reported $23.0 billion in revenue, up 48% from a year earlier, and adjusted earnings of $8.38 per share, well above consensus estimates. The company also increased its full-year revenue forecast to a range of $85 billion to $87 billion.

What's driving this optimism is not just domestic demand. According to Bank of America, sales of GLP-1 drugs-medications that help treat obesity and diabetes by reducing appetite-are rapidly gaining ground outside the U.S. In the most recent quarter, Lilly's diabetes injection Mounjaro saw sales jump 55% in Europe, 30% in Japan, and 93% in China. The bank believes that, given the larger pool of untreated patients abroad, international sales could eventually outpace those in the U.S.

Foundayo's Global Launch and Market Dynamics

Foundayo, Lilly's oral GLP-1 pill, is seen as a key catalyst for the company's next phase of growth. Unlike injectable treatments, the pill format could appeal to patients unwilling to take weekly shots, expanding the addressable market. Foundayo's U.S. launch brought in $98 million in the quarter, slightly below analyst expectations, but Bank of America expects the international rollout to be far more significant. The company has filed for approval in over 40 countries and plans to begin overseas launches in early 2027. Analysts estimate that about 60% of Foundayo's peak sales could come from outside the U.S., reflecting pent-up demand in markets where injectable drugs have faced supply constraints.

Lilly's main competitor, Novo Nordisk, has already launched its own oral GLP-1 drug, Wegovy, in some international markets, and both companies report strong demand for pill-based obesity treatments abroad. The race to capture global market share is intensifying, with supply chain and regulatory hurdles shaping the pace of expansion.

U.S. Pricing Pressures and Volume Trade-Offs

While international growth is accelerating, the U.S. market presents its own challenges. The launch of Medicare's GLP-1 Bridge program on July 1 expanded coverage for obesity drugs to roughly 20 million eligible Americans, increasing access for older patients. Early feedback suggests that most new users are patients who have not previously tried GLP-1 therapies, and both oral and injectable options are available through the program.

However, as more patients enter through insurance and cash-pay channels, net prices for GLP-1 drugs in the U.S. are falling. Bank of America estimates that Lilly's second-quarter U.S. net sales averaged about $580 per prescription, down 15% from a year earlier but stable compared to the prior quarter. The company's management argues that rising prescription volumes are more than offsetting price declines, but warns that if volume growth slows while prices continue to drop, the financial outlook could quickly change.

Pipeline Depth and Investor Considerations

Lilly's pipeline remains a key differentiator. The company is advancing late-stage assets such as Retatrutide, a next-generation triple-hormone injection that has shown weight loss results approaching those of bariatric surgery in clinical trials, with a U.S. regulatory filing planned for early 2027. Another candidate, Eloralintide, an amylin-based drug, has been added to Bank of America's model, reflecting the depth of Lilly's research portfolio. This diversification means Lilly is not dependent on a single product for future growth.

Shares of Eli Lilly closed at $1,192.52 on August 6, up nearly 2% on the day and close to their 52-week high of $1,249.45. At current levels, Bank of America's target implies about 13% upside over the next year. Still, the stock trades at a price-to-earnings ratio near 40, indicating that much of the anticipated growth is already reflected in the share price. Investors should be aware that a weak quarter in either volume or pricing could have an outsized impact at these valuations.

For those weighing a position in Lilly, the international launch of Foundayo is likely to be the most important swing factor, but it will not begin in earnest until early 2027. The company's ability to grow demand faster than prices fall-both in the U.S. and abroad-remains central to the investment case. As with other high-growth stocks, sizing a position according to personal risk tolerance is essential, especially when expectations are elevated. For a look at how other companies have responded to major growth catalysts, see this analysis of Palantir's recent earnings surge here.

According to Eli Lilly's second-quarter 2026 earnings release, the company reported $23.0 billion in revenue, a 48% increase from the same period a year earlier. Adjusted earnings per share reached $8.38, compared to a consensus estimate of $6.01. The company raised its full-year revenue guidance to $85 billion-$87 billion, up from its previous range of $82 billion-$85 billion. U.S. net sales per GLP-1 prescription averaged about $580, down 15% year over year, while international sales of Mounjaro grew sharply across Europe, Japan, and China.

GLP-1 drugs, including both injectable and oral forms, have become a major focus for pharmaceutical companies targeting obesity and diabetes. These medications work by mimicking hormones that regulate appetite and blood sugar, leading to weight loss and improved metabolic health for many patients. The rapid expansion of this drug class has intensified competition among manufacturers, driven up research investment, and raised questions about long-term pricing, insurance coverage, and access. As more countries approve new treatments and coverage expands, the balance between volume growth and pricing pressure will remain a central issue for both companies and investors.